Navigation Links
Viron to Present Data from Phase II Trial at American Heart Association Conference
Date:11/11/2009

LONDON, ON, Nov. 11 /PRNewswire/ - Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.

The presentation entitled, "Viral Anti-inflammatory Treatment of Unstable Coronary Syndromes: The VT-111 Acute Coronary Syndrome Trial," will disclose recent results from a Phase IIa trial evaluating VT-111, a serine protein inhibitor, in patients with Acute Coronary Syndromes receiving coronary stents. Dr. Tardif's presentation is scheduled for Wednesday, November 18, 2009, at 11:00 AM (ET) in Room W304gh of the Orange County Convention Center. A copy of the presentation will be available after the conference on Viron's website, www.vironinc.com.

About VT-111

VT-111, an immune-modulating protein therapeutic, is the world's first viral-derived human therapeutic. It is a novel inhibitor of the monocyte/macrophage influx to sites of injury and has demonstrated potent efficacy in preclinical models of acute injury in which inflammation plays a key role. VT-111 recently completed a Phase IIa trial of 48 patients with Acute Coronary Syndromes receiving coronary stents. In addition to advancing the cardiovascular program with a partner, Viron is moving to conduct appropriate preclinical studies prior to a clinical program to evaluate the effects of VT-111 in solid organ transplantation.

About Viron Therapeutics Inc. (www.vironinc.com)

Viron is a biopharmaceutical company pioneering the development of pathogen proteins, a revolutionary new class of drugs. These drugs leverage strategies evolved by pathogens to inactivate key targets in the human immune system. The Company's proprietary PROSPECT(TM) technology, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a platform for the discovery of new immune-modulating protein therapeutics. Its significant pipeline of products target critical pathways that have broad application to immune and inflammatory based diseases such as cardiovascular disease and rheumatoid arthritis. VT-111, the Company's lead compound, is in development to treat Acute Coronary Syndromes and solid organ transplant rejection.

SOURCE Viron Therapeutics Inc.


'/>"/>
SOURCE Viron Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders
2. RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products
3. The future of electricity may be found in environmentally friendly, thermoelectric cells
4. The future of electricity may be found in environmentally-friendly, thermoelectric cells
5. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
6. Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering
7. Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar
8. Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation
9. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
10. Hidden diversity in key environmental cleanup microbes found by systems biology assessment
11. How mercury becomes toxic in the environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
(Date:3/22/2017)... ... 21, 2017 , ... Proper glycosylation is critical for the ... and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is a growing ... , To meet this demand, the team at SCIEX has developed a Fast ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by the ... feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) and ...
(Date:3/22/2017)... PETACH TIKVAH, Israel , March 22, ... leading developer of adult stem cell technologies for neurodegenerative ... Executive Officer, will provide an update on new developments ... Annual Neuroscience Biopartnering and Investment Forum, being held ... Academy of Sciences. ...
Breaking Biology Technology:
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
Breaking Biology News(10 mins):